On June 6, 2018 Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, reported CEO, Carsten Thiel, Ph.D., will present at the at the Jefferies 2018 Global Healthcare Conference in New York City, NY (Press release, Abeona Therapeutics, JUN 6, 2018, View Source;p=RssLanding&cat=news&id=2353504 [SID1234527199]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event: Jefferies 2018 Global Healthcare Conference
Date: Thursday, June 7th
Presenter: Carsten Thiel, Ph.D., CEO
Presentation Time: 11:00 AM – 11:25 AM ET
Room Name: Ballroom I
Location: New York City, NY
Webcast: View Source
Abeona Recent Highlights
May 31st: Opening of Commercial Gene & Cell Therapy GMP Manufacturing Facility in Cleveland, Ohio
— The Elisa Linton Center for Rare Disease Therapies to support development of advanced gene and cell therapies for treatment of serious rare diseases.
— The GMP facility will have the capability to manufacture clinical and commercial grade products over Abeona’s multiple programs, including recessive dystrophic epidermolysis bullosa (RDEB) and Sanfilippo syndrome.
May 18th: Clinical Update on MPS IIIA Gene Therapy Trial at the 21st Annual ASGCT (Free ASGCT Whitepaper) Meeting
— Ongoing ABO-102 (AAV-SGSH) trial results demonstrate robust and durable clinical effects achieved throughout various timepoints post-administration.
— 18-month efficacy and safety data continue to demonstrate time- and dose-dependent reductions in underlying disease pathology, including decreased CSF and urine GAGs and improved liver volumes.
— 11 subjects enrolled through > 4,200 days cumulative follow up.
May 17th: Clinical Update from RDEB Gene & Cell Therapy Trial at the 21st Annual ASGCT (Free ASGCT Whitepaper) Meeting
— EB-101, the Company’s gene-corrected skin graft cell therapy for patients suffering from RDEB is safe and well-tolerated, with durable efficacy.
— Trial results demonstrate robust and durable clinical effects achieved throughout various timepoints post-administration.
— Completed Phase 1/2 clinical trial included seven patients with 42 gene-corrected EB-101 grafts, with the first patient treated over three years ago with lasting effects and closed wounds to date